Expertise in
4
conditions

Lin B. Shen

Holistic Medicine
2415 Bell Blvd, 
Bayside, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
4
conditions
2415 Bell Blvd, 
Bayside, NY 

Overview

Lin Shen is a Holistic Medicine provider practicing medicine in Bayside, New York.

Ms. Shen is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Gastroesophageal Junction Cancer, Gallbladder Adenocarcinoma, Febrile Neutropenia, Hepato-Pancreato-Biliary Surgery, and Endoscopy.

She is actively involved in clinical research, co-authoring 1049 peer reviewed articles and participating in 29 clinical trials.

Specialties

Holistic Medicine

Licenses

Acupuncturist in NY

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

2415 Bell Blvd, Bayside, NY 11360

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
Enrollment Status: Recruiting
Publish Date: August 27, 2026
Intervention Type: Drug
Study Drug: BL-B01D1
Study Phase: Phase 1
A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 10, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy Versus Placebo Combined With Postoperative Adjuvant Chemotherapy in Patients With Gastric or Esophagogastric Junction Adenocarcinoma After Radical Gastrectomy
A Multicenter, Randomized, Double-Blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy Versus Placebo Combined With Postoperative Adjuvant Chemotherapy in Patients With Gastric or Esophagogastric Junction Adenocarcinoma After Radical Gastrectomy
Enrollment Status: Active_not_recruiting
Publish Date: July 07, 2026
Intervention Type: Biological
Study Drug: JS001
Study Phase: Phase 3
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Enrollment Status: Completed
Publish Date: April 30, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma
A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: AK104
Study Phase: Phase 3
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drug: SI-B003
Study Phase: Phase 1
A Randomized, Double-Blind, Multi-Center Phase II/III Clinical Study of PD-L1 Antibody/TGF-βRII (SHR-1701) Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin Versus Placebo Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin as Perioperative Treatment in Subjects With Resectable Gastric Cancer or Gastroesophageal Junction Cancer
A Randomized, Double-Blind, Multi-Center Phase II/III Clinical Study of PD-L1 Antibody/TGF-βRII (SHR-1701) Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin Versus Placebo Plus Tegafur Gimeracil Oteracil Potassium and Oxaliplatin as Perioperative Treatment in Subjects With Resectable Gastric Cancer or Gastroesophageal Junction Cancer
Enrollment Status: Terminated
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: SHR-1701 Injection
Study Phase: Phase 2/Phase 3
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3
A Multicenter, Open-label, Phase I Clinical Study: A Dose-finding and Dose Expansion Study to Evaluate ORIN1001 Monotherapy and Its Combination in Patients With Advanced Solid Malignant Tumors
A Multicenter, Open-label, Phase I Clinical Study: A Dose-finding and Dose Expansion Study to Evaluate ORIN1001 Monotherapy and Its Combination in Patients With Advanced Solid Malignant Tumors
Enrollment Status: Completed
Publish Date: May 30, 2025
Intervention Type: Drug
Study Drug: ORIN1001
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

1049 Total Publications

Correction: The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation.
Correction: The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation.
Journal: Human cell
Published: August 13, 2026
Similar Doctors
Expertise in
28
conditions
Dr. Min J. Zhang
Holistic Medicine
Expertise in
28
conditions
Dr. Min J. Zhang
Holistic Medicine
Referral may be required

Office

247 W 35th St Fl 10, 
New York, NY 
 (11.8 miles away)
212-244-3919
Languages Spoken:
English

Min Zhang is a Holistic Medicine provider practicing medicine in New York, New York. Mr. Zhang is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Liver Failure, Balantidiasis, Gallbladder Disease, Bone Marrow Aspiration, and Endoscopy.

Expertise in
1
conditions
Dr. Henry C. Lee
Holistic Medicine
Expertise in
1
conditions
Dr. Henry C. Lee
Holistic Medicine
Referral may be required

E.W. Natural Healing Acupuncture P.C.

21 W Nicholai St, 
Hicksville, NY 
 (13.2 miles away)
516-822-6722
Languages Spoken:
English

Henry Lee is a Holistic Medicine provider practicing medicine in Hicksville, New York. Mr. Lee is highly rated in 1 condition, according to our data. His clinical expertise encompasses Succinic Semialdehyde Dehydrogenase Deficiency.

Expertise in
41
conditions
Hui J. Wang
Holistic Medicine
Expertise in
41
conditions
Hui J. Wang
Holistic Medicine
Referral may be required
227 Madison St, Medical Staff Office-room 1249, 
New York, NY 
 (12.0 miles away)
212-238-7614
Languages Spoken:
English

Hui Wang is a Holistic Medicine provider practicing medicine in New York, New York. Ms. Wang is highly rated in 41 conditions, according to our data. Her clinical expertise encompasses Gallbladder Disease, Alveolar Echinococcosis, Liver Failure, Endoscopy, and Spinal Fusion.

Frequently Asked Questions about Lin B. Shen

How do I make an appointment with Lin B. Shen?

You can book an appointment with Lin B. Shen by calling their office at 718-357-3638. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Lin B. Shen a top-rated expert for Gastroesophageal Junction Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Lin B. Shen is classified as an Distinguished expert for Gastroesophageal Junction Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Lin B. Shen specialize in?

While Lin B. Shen is a Holistic Medicine, they have specific expertise in Gastroesophageal Junction Cancer, Gallbladder Adenocarcinoma, and Febrile Neutropenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Holistic Medicine.

Does Lin B. Shen participate in research or clinical trials?

Yes. Lin B. Shen has published 1049 articles and abstracts on conditions like Gastroesophageal Junction Cancer. You can view a list of Lin B. Shen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Shen's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile